Just 3 in 10 patients who experienced a nonfatal opioid overdose (OD) were given follow-up medication to prevent another overdose, and the average treatment lasted less than 6 months.
For those who have experienced a nonfatal opioid overdose, access to medication for opioid use disorder—naltrexone, methadone, and buprenorphine—are crucial, as these patients are at a higher risk for subsequent nonfatal and fatal overdoses. These medications are known to reduce opioid withdrawal symptoms and suppress the desire to use opioids.
However, new study findings indicate1 that just 3 in 10 patients revived in an emergency department or ambulance were given follow-up medication to prevent another overdose. In addition to low rates of treatment with these medications, the average treatment lasted less than 6 months.
The study focused on residents in Massachusetts, as the state has been particularly affected by the epidemic, with opioid overdose deaths tripling from 2010 to 2016. Researchers used 7 individually linked data sets from Massachusetts government agencies. A total of 17,568 people who had experienced a nonfatal opioid overdose between January 2012 and December 2014 were identified.
Following the overdose, 11% of participants received methadone for a median of 5 months. For these patients, all-cause and opioid-related mortality rates were cut by 50% compared to those not on any medication after 1 year. For the 17% of patients who received buprenorphine for a median of 4 months, their risk of mortality dropped by 40% after 1 year.
Meanwhile, for the small percentage of patients (6%) who were treated with naltrexone for a median of 1 month, there was no observed association. The researchers noted that this finding could be due to the limited treatment size.
According to an accompanying editorial2, stigma is at the root of these low rates, and short treatment courses highlight a need for interventions to facilitate treatment retention.
They also note that: “Treatment facilities often lack medical personnel who can prescribe medications; even if staff at opioid treatment programs are able to dispense methadone, they may not be waivered to prescribe buprenorphine. In addition, insurers may not cover all forms of medication-assisted treatment, and when they do, coverage is usually subjected to limits on duration that lessen treatment effectiveness.”
However, there are several strategies that can increase medication-assisted treatment delivery to those at risk of an overdose, including initiating treatment in the emergency department and linking them to treatment by a primary care physician waivered to continue proving the medication, and engaging people with opioid use disorder in the criminal justice setting into treatment to reduce opioid use and overdoses after they reenter the community.
“A great part of the tragedy of this opioid crisis is that, unlike in previous crises American has seen, we now possess effective treatment strategies that could address it and save many lives, yet tens of thousands of people die each year because they have not received these treatments,” the authors wrote.
In an effort to improve access to and affordability of these treatment options for those who need it, the FDA approved the first generic version of Suboxone (buprenorphine and naloxone) last week. Along with the approval, FDA Commissioner Scott Gottlieb, MD, highlighted the importance of addressing the stigma surrounding medication-assisted treatments, stating that, when coupled with other social, medical, and psychological services, these treatments are often the most effective approach for opioid dependence.
References:
1. Larochelle M, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study [published online June 19, 2018]. Ann Intern Med. doi: 10.7326/M17-3107.
2. Volkow N, Wargo E. Overdose presention through medical treatment of opioid use disorders [published online June 19, 2018]. Ann Intern Med. doi: 10.7326/M18-1397.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen